CYTR News and Press, CytRx Corporation From 11/30/21

Issues Presentation on Plans, Including Potential Sources of Funding and Benefits to the Las Vegas Community Highlights Centurion BioPharma's Recent Momentum in the Research and Development of Cancer Drugs CytRx Corporation (OTCQB: CYTR) (“CytRx” or the...

Centurion BioPharma Executive Chairman Steven A. Kriegsman Will Present to the Office of the Governor of Nevada and Las Vegas Global Economic Alliance on Thursday, November 18, 2021 Highlights Opportunity to Build Best-in-Class Cancer Treatment Center in Las Vegas, Nevada and ...

FDA Recommends Orphazyme Provides Supplemental Information and Analyses FDA Offers to have Further Interactions with Orphazyme to Identify Path to Resubmission for Arimoclomol in NPC CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”...

Highlights Early Efficacy of CytRx’s Licensed Drug Aldoxorubicin in ImmunityBio's Phase 2 Trial of Nant Cancer Vaccine for Third Line or Greater Pancreatic Cancer Patients Notes 90% of All Evaluable Patients and 87% of Patients With Extremely Advanced Disease Upon Enrol...

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that Steven A. Kriegsman, Chairman and Chief Exe...

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that Steven A. Kriegsman, the Company’s C...

The reason for having a home bias is usually fear of missing information. Therefore, investors with a home bias should not invest in US-traded dark stocks, of non-reporting companies. A much better alternative is US-traded and foreign nanocaps that are filing financial reports. In thi...

CytRx (OTCQB:CYTR) highlights that Orphazyme (NASDAQ:ORPH) has published the results from a Phase 2/3 trial of arimoclomol in Niemann-Pick disease type C (NPC) in the peer-reviewed Journal of Inherited Metabolic Disease. ORPH shares up 4.1% premarket at $5.54. NPC is a rare pro...

12-Month Study of Arimoclomol Showed a Clinically Meaningful Treatment Effect, Corresponding to a Reduction in Disease Progression Highlights Arimoclomol is Under Regulatory Review in Europe, With a Decision Expected in Q4 2021 Notes Orphazyme Stated it Conti...

CytRx Corporation (OTCQB:CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the second quarter ended June ...